Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Rosiñol, Laura  [Clear All Filters]
Journal Article
Rodríguez-Lobato L-G, Martínez-Roca A, Castaño-Díez S, Palomino-Mosquera A, Gutiérrez-García G, Pedraza A, Suárez-Lledó M, Rovira M, Martínez C, de Larrea CFernández, et al. The avoidance of G-CSF and the addition of prophylactic corticosteroids after autologous stem cell transplantation for multiple myeloma patients appeal for the at-home setting to reduce readmission for neutropenic fever. PLoS One. 2020;15(11):e0241778.
Mateos M-V, Oriol A, Rosiñol L, de Arriba F, Puig N, Martín J, Martínez-López J, Echeveste M-A, Sarrá J, Ocio E, et al. Bendamustine, bortezomib and prednisone for the treatment of newly diagnosed multiple myeloma patients: results of a prospective phase 2 Spanish/Pethema trial. Haematologica. 2015.
Sonneveld P, Goldschmidt H, Rosiñol L, Bladé J, Lahuerta JJosé, Cavo M, Tacchetti P, Zamagni E, Attal M, Lokhorst HM, et al. Bortezomib-Based Versus Nonbortezomib-Based Induction Treatment Before Autologous Stem-Cell Transplantation in Patients With Previously Untreated Multiple Myeloma: A Meta-Analysis of Phase III Randomized, Controlled Trials. J Clin Oncol. 2013.
Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, Hajek R, Facon T, Ludwig H, Oriol A, Goldschmidt H, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2015.
Sonneveld P, Dimopoulos MA, Boccadoro M, Quach H, P Ho J, Beksac M, Hulin C, Antonioli E, Leleu X, Mangiacavalli S, et al. Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. N Engl J Med. 2023.
Tovar N, de Larrea CFernández, Pedrosa F, Aróstegui JI, Cibeira MTeresa, Rosiñol L, Elena M, Filella X, Yagüe J, Bladé J. Differential humoral responses against heat-shock proteins after autologous stem cell transplantation in multiple myeloma. Ann Hematol. 2013.
Pedraza A, Salas MQueralt, Rodríguez-Lobato LGerardo, Escribano-Serrat S, Suárez-Lledó M, Martínez-Cebrian N, Solano MTeresa, Arcarons J, Rosiñol L, Gutiérrez-García G, et al. EASIX SCORE CORRELATES WITH ENDOTHELIAL DYSFUNCTION BIOMARKERS AND PREDICTS RISK OF ACUTE GRAFT-VERSUS-HOST DISEASE AFTER ALLOGENEIC TRANSPLANTATION. Transplant Cell Ther. 2023.
Gutiérrez-García G, Cibeira MTeresa, Rovira M, de Larrea CFernández, Tovar N, Rodríguez-Lobato LGerardo, Rosiñol L, Marín P, Solano-Vega J, Suárez-Lledó M, et al. Improving security of autologous hematopoietic stem cell transplant in patients with light-chain amyloidosis. Bone Marrow Transplant. 2019.
Facon T, Moreau P, Martin TG, Spicka I, Oriol A, Koh Y, Lim A, Mikala G, Rosiñol L, Yağci M, et al. Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis. Hematol Oncol. 2022.
Molina-Andújar A, Tovar N, Cuadrado E, de Anta NCastrejón, Revuelta I, Cucchiari D, Cofan F, Esforzado N, M Cibeira T, Rosiñol L, et al. Kidney Transplantation in Monoclonal Immunoglobulin Deposition Disease: A Report of 6 Cases. Am J Kidney Dis. 2021.
Sanfeliciano TContreras, Roca CAgullo, Martínez-López J, Oriol A, Blanchard M-J, Ríos-Tamayo R, Sánchez JMartín, M Iñigo B, Sureda A, Garcia M-TTHernande, et al. Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma. Blood Adv. 2022.
Schjesvold FH, Dimopoulos M-A, Delimpasi S, Robak P, Coriu D, Legiec W, Pour L, Spicka I, Masszi T, Doronin V, et al. Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study. Lancet Haematol. 2022.
Tovar N, de Larrea CFernández, Aróstegui JI, Cibeira MTeresa, Rosiñol L, Rovira M, Elena M, Filella X, Yagüe J, Bladé J. Natural history and prognostic impact of oligoclonal humoral response in patients with multiple myeloma after autologous stem-cell transplantation: long-term results from a single institution. Haematologica. 2013.
Salas MQueralt, Pedraza A, Charry P, Suárez-Lledó M, Rodríguez-Lobato LGerardo, Brusosa M, Solano MTeresa, Serrahima A, Nomdedeu M, Cid J, et al. Post-transplant Cyclophosphamide and Tacrolimus for GVHD Prevention Allo-HCT from HLA-Matched Donors Generates more Advantages than Limitations. Transplant Cell Ther. 2023.
Salas MQueralt, Charry P, Pedraza A, Martínez-Cibrián N, Solano MTeresa, Domenech A, Suárez-Lledó M, Nomdedeu M, Cid J, Lozano M, et al. PTCY and Tacrolimus for GVHD Prevention for Older Adults Undergoing HLA-Matched Sibling and Unrelated Donor AlloHCT. Transplant Cell Ther. 2022.
Suárez-Lledó M, Marcos MAÁngeles, Cuatrecasas M, Bombi JAntoni, Fernández-Avilés F, Magnano L, Martínez-Cibrián N, Llobet N, Rosiñol L, Gutiérrez-García G, et al. Quantitative PCR is faster, more objective and more reliable than immunohistochemistry for the diagnosis of Cytomegalovirus Gastrointestinal disease in allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2019.